Post Orgasmic Illness Syndrome (POIS) and Delayed Onset Muscle Soreness (DOMS): Do They Have Anything in Common?

by Balázs Sonkodi, Zsolt Kopa, Péter Nyirády
Published 2021-07-01

New Insights into Diagnosis and Treatment of Renal Cell Carcinoma, Bladder Cancer, and Prostate Cancer

by Piotr L. Chlosta, Tomasz Golabek, Péter Nyirády
Published 2017-01-01

Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data

by Henning Reis, Ulrich Krafft, Christian Niedworok, Orsolya Módos, Thomas Herold, Mark Behrendt, Hikmat Al-Ahmadie, Boris Hadaschik, Peter Nyirady, Tibor Szarvas
Published 2018-01-01

Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients

by Csilla Olah, Stephan Tschirdewahn, Michèle J. Hoffmann, Ulrich Krafft, Boris Hadaschik, Peter Nyirady, Attila Szendröi, Orsolya Módos, Anita Csizmarik, Ilona Kovalszky, Henning Reis, Tibor Szarvas
Published 2020-10-01

Bosniak category III cysts are more likely to be malignant than we expected in the era of multidetector computed tomography technology

by Pal Bata, Adam Domonkos Tarnoki, David Laszlo Tarnoki, Attila Marcell Szasz, Gergely Poloskei, Bence Fejer, Janos Gyebnar, Peter Nyirady, Viktor Berczi, Kinga Karlinger, Attila Szendroi
Published 2014-01-01

MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients

by Tibor Szarvas, Michèle J. Hoffmann, Csilla Olah, Eszter Szekely, Andras Kiss, Jochen Hess, Stephan Tschirdewahn, Boris Hadaschik, Vera Grotheer, Peter Nyirady, Anita Csizmarik, Melinda Varadi, Henning Reis
Published 2021-12-01

High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy

by Ulrich Krafft, Csilla Olah, Henning Reis, Claudia Kesch, Christopher Darr, Viktor Grünwald, Stephan Tschirdewahn, Boris Hadaschik, Orsolya Horvath, Istvan Kenessey, Peter Nyirady, Melinda Varadi, Orsolya Modos, Anita Csizmarik, Tibor Szarvas
Published 2021-05-01